Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
University of Florida
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03513328CT.gov Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation | — | Completed | — | — | — |
NCT01821781CT.gov Immune Disorder HSCT Protocol | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hemophagocytic Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Thiotepa (this asset) | University of Florida | P2 | BB · 64 |
| Etoposide | Beijing Tongren Hospital | P4 | BBB |
| Pegaspargase | Beijing Tongren Hospital | P4 | BB |
| Adriamycin | The First Affiliated Hospital of Soochow University | P4 | BB |
| Cis-Diamminedichloroplatinum Ii | Zhengzhou University | P4 | BB |
| Zanubrutinib | The First Affiliated Hospital of Soochow University | P4 | BB |
| Dexasone | Zhengzhou University | P4 | BB |
| Rituximab | The First Affiliated Hospital of Soochow University | P4 | BB |
| Ruxolitinib | Zhengzhou University | P4 | B |
+23 more in the Hemophagocytic Syndrome cohort
Other indications for Thiotepa
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Graft Versus Host Disease | — | P4 | BBB · 73 |
| Myelodysplastic/Myeloproliferative Neoplasm | — | P2/3 | BBB · 72 |
| Juvenile Myelomonocytic Leukemia | — | P3 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Thiotepa in Hemophagocytic Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/thiotepa-hemophagocytic-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →